CA
MDGL icon

Cornerstone Advisory’s Madrigal Pharmaceuticals MDGL Stock Holding History

Cornerstone Advisory’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-50
Closed -$4K – 536
2021
Q4 		$4K Buy
+50
New +$4.11K ﹤0.01% 687

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Cornerstone Advisory's MDGL Position: Q1 2022 in Review

Cornerstone Advisory sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2022, closing a stake of 50 shares — an estimated $4K sold.

Cornerstone Advisory first reported a position in MDGL in Q4 2021 and held it in 1 quarter. The position peaked at $4K in Q4 2021. 140 funds tracked by Wall St. Rank hold MDGL as of Q1 2022.

  • Cornerstone Advisory reported no remaining Madrigal Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Cornerstone Advisory sold 50 Madrigal Pharmaceuticals shares in Q1 2022, an estimated $4K.
  • Cornerstone Advisory first reported a position in Madrigal Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Cornerstone Advisory's Madrigal Pharmaceuticals position peaked at $4K in Q4 2021.
  • 140 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2022.

Based on Cornerstone Advisory's 13F filing for Q1 2022, filed 20 May 2022.